Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Generation and characterization of chimeric recombinant AAV vectors.

Bernd Hauck1, Ling Chen, Weidong Xiao

  • 1Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis.

Human gene therapy. Clinical development·2015
Same author

Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors.

PloS one·2014
Same author

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

The New England journal of medicine·2013
Same author

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.

Molecular therapy : the journal of the American Society of Gene Therapy·2012
Same author

Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle.

Current drug delivery·2012
Same author

A model of cancer stem cells derived from mouse induced pluripotent stem cells.

PloS one·2012
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Cell-penetrating asymmetric siRNA targeting MyD88 suppresses inflammasome-driven ocular degeneration and angiogenesis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Discovery of circadian clock activators with anti-obesity efficacy via suppression of adipocyte development and hypertrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Researchers created novel chimeric adeno-associated virus (AAV) vectors combining AAV1 and AAV2 properties. These chimeric AAV vectors show improved tissue tropism and purification efficiency for gene therapy applications.

Area of Science:

  • Gene therapy
  • Viral vectors
  • Molecular biology

Background:

  • Recombinant adeno-associated virus (AAV) vectors are widely used in gene therapy.
  • AAV serotype 2 (AAV2) vectors are common, but AAV serotype 1 (AAV1) vectors show higher muscle transduction efficiency.
  • AAV2 vectors are easily purified using heparin columns, a property lacking in AAV1 vectors.

Purpose of the Study:

  • To develop a novel chimeric AAV vector combining the high transduction efficiency of AAV1 in muscle with the purification advantages of AAV2.
  • To create a versatile AAV vector with combined properties of different serotypes for enhanced gene delivery.

Main Methods:

  • Generation of chimeric AAV vectors using a mixture of AAV helper plasmids encoding both AAV1 and AAV2 serotypes.
  • Purification of chimeric AAV vectors using heparin chromatography.

Related Experiment Videos

  • Characterization of chimeric vectors using neutralizing antibody assays and in vivo expression studies in muscle and liver.

    • Main Results:

    • Chimeric AAV vectors were successfully generated and purified via heparin column chromatography.
    • Neutralizing antibody assays confirmed that chimeric vectors are neutralized by both AAV1 and AAV2 antisera.
    • In vivo studies demonstrated that chimeric vectors exhibit AAV1-like expression in muscle and AAV2-like expression in the liver, effectively combining the tropism of both parent serotypes.

    Conclusions:

    • A straightforward method was developed to create chimeric AAV vectors with combined properties of different serotypes.
    • These chimeric vectors offer a promising strategy for enhancing gene therapy by leveraging the distinct advantages of multiple AAV serotypes.
    • The study provides a foundation for developing more efficient and versatile AAV-based gene delivery systems.